Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Infosys Limited — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Infosys Limited trades at $10.73 (market cap $41.74B). The key difference: Infosys Limited is far larger — about 3.3× Halozyme Therapeutics Inc. Common Stock's market cap, and Infosys Limited pays a 4.89% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Infosys Limited for 27 Days on average.
| HALO | INFY | |
|---|---|---|
Market Cap | $12.58B | $41.74B |
Volume | 2,179,278 | 31,354,285 |
Sector | Health | Technology |
52-Week High | $115.22 | $20.22 |
52-Week Low | $61.63 | $10.49 |
Typical Hold Time | 1 Days | 27 Days |
Enterprise Value | $14.49B | $39.48B |
Dividend Yield | — | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INFY trades at $10.73, up 1.71% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025, with a net income margin of 16.37% and a P/E ratio of 13.21. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. News highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation.
The outlook is cautious due to bearish technicals and a slight decline in 2026 cash flow projections. Analyst consensus is a 'Hold' with a $11.48 price target, suggesting limited upside. Risks include competitive pressures in IT services and macroeconomic headwinds affecting Western IT spending. The stock's current valuation appears reasonable, but growth catalysts from AI initiatives need to materialize to support a bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
